$3.79
0.00% yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US81728J1097
Symbol
SRTS

Sensus Healthcare, Inc. Stock price

$3.79
-0.23 5.72% 1M
-0.92 19.53% 6M
-3.13 45.23% YTD
-3.01 44.26% 1Y
-3.11 45.07% 3Y
-0.12 3.07% 5Y
-2.06 35.21% 10Y
-2.06 35.21% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.00 0.00%

Key metrics

Basic
Market capitalization
$62.3m
Enterprise Value
$37.8m
Net debt
positive
Cash
$24.5m
Shares outstanding
16.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.7 | 2.0
EV/Sales
1.1 | 1.2
EV/FCF
17.4
P/B
1.2
Financial Health
Equity Ratio
89.8%
Return on Equity
11.9%
ROCE
-10.6%
ROIC
-12.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$35.6m | $31.5m
EBITDA
$-5.2m | $-8.7m
EBIT
$-5.4m | $-8.6m
Net Income
$-3.0m | $-5.8m
Free Cash Flow
$2.2m
Growth (TTM | estimate)
Revenue
-13.8% | -24.7%
EBITDA
-142.4% | -204.1%
EBIT
-145.5% | -206.1%
Net Income
-132.3% | -186.6%
Free Cash Flow
3.8%
Margin (TTM | estimate)
Gross
48.0%
EBITDA
-14.6% | -27.5%
EBIT
-15.3%
Net
-8.4% | -18.3%
Free Cash Flow
6.1%
More
EPS
$-0.2
FCF per Share
$0.1
Short interest
3.6%
Employees
54
Rev per Employee
$770.0k
Show more

Is Sensus Healthcare, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Sensus Healthcare, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Sensus Healthcare, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Sensus Healthcare, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Sensus Healthcare, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
36 36
14% 14%
100%
- Direct Costs 19 19
15% 15%
52%
17 17
32% 32%
48%
- Selling and Administrative Expenses 15 15
52% 52%
42%
- Research and Development Expense 7.46 7.46
124% 124%
21%
-5.21 -5.21
142% 142%
-15%
- Depreciation and Amortization 0.22 0.22
37% 37%
1%
EBIT (Operating Income) EBIT -5.43 -5.43
145% 145%
-15%
Net Profit -3.01 -3.01
132% 132%
-8%

In millions USD.

Don't miss a Thing! We will send you all news about Sensus Healthcare, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sensus Healthcare, Inc. Stock News

Neutral
Business Wire
about one month ago
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created positio...
Neutral
Business Wire
about one month ago
BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the pa...
Neutral
Seeking Alpha
about 2 months ago
Sensus Healthcare, Inc. ( SRTS ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Joseph Sardano - Co-Founder, Chairman & CEO Michael Sardano - President, General Counsel, Corporate Secretary & Director Javier Rampolla - Chief Financial Officer Conference Call Participants Tirth Patel - Lippert/Heilshorn & Associates, Inc. Anthony Vendetti - Maxim Group LLC, Research Divi...
More Sensus Healthcare, Inc. News

Company Profile

Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The firm's portfolio of treatment devices includes the SRT-100, SRT-100+ and SRT-100 Vision. Its main product, superficial radiation therapy (SRT), a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.

Head office United States
CEO Joseph Sardano
Employees 54
Founded 2010
Website sensushealthcare.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today